CLT 1081
Alternative Names: CLT-1081Latest Information Update: 09 Mar 2022
At a glance
- Originator Cellarity
- Class Antianaemics; Small molecules
- Mechanism of Action Fetal haemoglobin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Sickle cell anaemia
Most Recent Events
- 27 Jan 2022 Early research in Sickle cell anaemia in USA (Parenteral)
- 27 Jan 2022 Pharmacodynamics data from in vitro study for treatment of Sickle cell disease by pairing machine learning with high-resolution single cell RNA sequencing maps of adult and fetal human erythropoiesis released by Cellarity